VanEck Associates
AMRX icon

VanEck Associates’s Amneal Pharmaceuticals AMRX Stock Holding History

VanEck Associates’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,186
Closed -$17K – 833
2019
Q1 		$17K Buy
1,186
+1
+0.1% +$13 ﹤0.01% 822
2018
Q4 		$16K Buy
1,185
+23
+2% +$414 ﹤0.01% 788
2018
Q3 		$26K Buy
+1,162
New +$24.5K ﹤0.01% 778

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VanEck Associates's AMRX Position: Q2 2019 in Review

VanEck Associates sold out of Amneal Pharmaceuticals (AMRX) in Q2 2019, closing a stake of 1,186 shares — an estimated $17K sold.

VanEck Associates first reported a position in AMRX in Q3 2018 and held it in 3 quarters. The position peaked at $26K in Q3 2018. 129 funds tracked by Wall St. Rank hold AMRX as of Q2 2019.

  • VanEck Associates reported no remaining Amneal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • VanEck Associates sold 1,186 Amneal Pharmaceuticals shares in Q2 2019, an estimated $17K.
  • VanEck Associates first reported a position in Amneal Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • VanEck Associates's Amneal Pharmaceuticals position peaked at $26K in Q3 2018.
  • 129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2019.

Based on VanEck Associates's 13F filing for Q2 2019, filed 7 Aug 2019.